NCT07465757Phase 2Recruiting

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

Study sponsor: Puma Biotechnology, Inc. · PBYI

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-03-31Estimated

Enrollment · participants50Estimated

Source updated2026-09-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-14 · 1 field changed

Recruitment status changed

− Before

~~Not yet recruiting~~

+ After

Recruiting

Check registry source

Study details

Conditions studied

Small Cell Lung Cancer ( SCLC )

Treatments or interventions studied

AlisertibDrugAlso known as PB-8237, MLN8237
AlisertibDrugAlso known as PB-8237, MLN8237
AlisertibDrugAlso known as PB-8237, MLN8237
AlisertibDrugAlso known as PB-8237, MLN8237
AlisertibDrugAlso known as PB-8237, MLN8237
PaclitaxelDrug

Primary outcomes · main study measures

measure: Percentage of Participants with Treatment-Emergent Adverse Events (Adverse Events and Serious Adverse Events); description: Treatment emergent adverse events are those events reported on or after the first dose of investigational product and up to 28 days after the last dose.; timeFrame: From date of first dose through last dose plus 28 days, assessed up to 24 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history